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doi:10.1Objectives: Clinical translation of tissue-engineered heart valves requires valve competency and lack of stenosis
in the short and long term. Early studies of engineered valves showed promise, although lacked complete defi-
nition of valve function. Building on prior experiments, we sought to define the in vivo changes in structure
and function of autologous engineered pulmonary valved conduits.
Methods:Mesenchymal stem cells were isolated from neonatal sheep bone marrow and seeded onto a bioresorb-
able scaffold. After 4 weeks of culture, valved conduits were implanted. Valve function, cusp, and conduit dimen-
sions were evaluated at implantation (echocardiography), at the experimental midpoint (magnetic resonance
imaging), and at explant, at 1 day, and 1, 6, 12, or 20 weeks postoperatively (direct measurement, echocardiog-
raphy). Histologic evaluation was performed.
Results:Nineteen animals underwent autologous tissue-engineered valved conduit replacement. At implantation,
valved conduit function was excellent; maximum transvalvular pressure gradient by Doppler echocardiography
was 17 mm Hg; most valved conduits showed trivial pulmonary regurgitation. At 6 postoperative weeks, valve
cusps appeared less mobile; pulmonary regurgitation was mild to moderate. At 12 weeks or more, valved conduit
cusps were increasingly attenuated and regurgitant. Valved conduit diameter remained unchanged over 20 weeks.
Dimensional measurements by magnetic resonance imaging correlated with direct measurement at explant.
Conclusions: We demonstrate autologous engineered tissue valved conduits that function well at implantation,
with subsequent monitoring of dimensions and function in real time by magnetic resonance imaging. In vivo
valves undergo structural and functional remodeling without stenosis, but with worsening pulmonary regurgita-
tion after 6 weeks. Insights into mechanisms of in vivo remodeling are valuable for future iterations of engineered
heart valves. (J Thorac Cardiovasc Surg 2010;139:723-31)/B
SAlthough much progress has been made in the treatment of
congenital heart disease, valve replacement technologies for
children continue to present distinct clinical challenges. For
children, currently available bioprosthetic and mechanical
valve replacement devices are limited by lack of growth; pe-
diatric patients outgrow valve replacement devices and sub-
sequently require multiple reoperations to accommodate an
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Tlifespan are generally well matched in adult populations, the
increasing life expectancy of children with congenital heart
disease intensifies the requirement for valve durability. Al-
though more durable, mechanical valves are thrombogenic;
implantation of a mechanical valve commits a patient to
long-term postoperative anticoagulation and its attendant
morbidities. In addition, pediatric patients commonly
require reconstruction of the pulmonary valve and right ven-
tricular outflow tract, thereby necessitating a valved conduit,
a different device from that which is designed for stented or
stentless valve replacement applications in adults.
These distinct design inputs for pediatric patients have led
to investigation of tissue engineering approaches for pulmo-
nary valve and right ventricular outflow tract replacement.1-3
Tissue-engineered heart valves are living tissues offering
growth potential and present a possible solution to this chal-
lenge. Previous experiments in which autologous cells were
seeded onto bioresorbable scaffolds and implanted in an in
vivo model have demonstrated the feasibility and potential
strengths of this approach.1-3
However, insufficient long-term data have been collected
to confidently evaluate the long-term function of engineered
valves, a requirement for clinical translation. Building onrdiovascular Surgery c Volume 139, Number 3 723
Abbreviations and Acronyms
ANOVA ¼ analysis of variance
DMEM ¼ Dulbecco’s modified Eagle’s medium
FBS ¼ fetal bovine serum
MRI ¼ magnetic resonance imaging
MSC ¼ mesenchymal stem cell
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Sprior experiments, we hypothesized that autologous, stem
cell–based engineered valved conduits could be successfully
implanted into the circulation, with acceptable initial valve
function. We sought to understand the process of tissue-
engineered valved conduit remodeling and to evaluate valve
function over time in a large in vivo series. To our knowl-
edge, this series of experiments provides a sufficiently large
number of observations to allow the meaningful evaluation
of intermediate-term performance of implanted tissue-
engineered heart valves. We further sought to establish re-
producible methods of monitoring in vivo valve function
using cardiac magnetic resonance imaging (MRI).
MATERIALS AND METHODS
Autologous valved conduits were created and implanted into sheep,
which were then monitored by cardiac MRI at the experimental midpoint.
Animals were grouped and monitored according to the schematic represen-
tation shown in Figure 1. Valved conduits were explanted at the experimen-
tal end point, within the first 24 hours (n¼ 7), and at 1 (n¼ 3), 6 (n¼ 3), 12
(n ¼ 3), or 20 weeks (n ¼ 3) after implantation.
Animals
Female sheep (Ovis aries,Dorset subspecies) were obtained at 4weeks of
age, weighing approximately 10 kg. Bonemarrow aspiration was performed
twice on each animal; at 5 and 6weeks of age, 10mL/kg of bonemarrowwas
harvested from the iliac crest under general anesthesia. Use of experimental
sheep was approved by the Institutional Animal Care and Use Committee of
Children’s Hospital Boston. Animals were cared for by a veterinarian in
accordance with the ‘‘Guide for the Care and Use of Laboratory Animals.’’
Cell Isolation and Expansion
Bone marrow was centrifuged on a Ficoll gradient (Sigma Chemical Co, St
Louis, Mo) and the mononuclear fraction was plated on uncoated plates in me-
dium containingDulbecco’smodifiedEagle’smedium (DMEM)with high glu-
cose, 10% fetal bovine serum (FBS), 10% autologous serum, 10 mmol/L
HEPES buffer, and 13 antibiotic/antimycotic. Mesenchymal stem cells
(MSCs) were isolated by their avid adherence to tissue culture plates as previ-
ously reported,1,4,5 passaged, and expanded in basal medium containing
DMEM with high glucose, 10% FBS, 13 antibiotic/antimycotic, and 10
mmol/L HEPES buffer. Cells were expanded by plating at a density of 104
cells/cm2 and passaged every 3 days when 70% to 80% confluence was
achieved. Cell passaging continued until approximately 1 billion cells were
expanded for eachvalved conduit.Aspreviously reported, 1monthwas required
from the harvest of bone marrow to the time of cell seeding on the scaffold.1
Scaffold Properties and Assembly
Sheets of nonwoven scaffold containing 50% fibers of polyglycolic acid
and 50% fibers of poly-L-lactic acid (Concordia Medical, Warwick, RI)
were assembled into a valved conduit bymanual andmachine needle punch-724 The Journal of Thoracic and Cardiovascular Surging, according to methods established in our laboratory,1 based on normal
dimensions of the ovine right ventricular outflow tract (data not shown).
Custom Tension Device and Scaffold Preparation for
Seeding
To immobilize the valved conduit, to prevent geometric changes during
culture, and to provide a homogeneous surface for cell seeding, we fabri-
cated a custom device for valved conduits in 3-dimensional culture.6 The
valved conduit scaffold was mounted onto gaskets and tied into position
with silk suture material, then sewn circumferentially to the tension device
at approximately the level of the cusp base and cusp free edge (Figure 2).
The valved conduit was then placed inside a 150-mm glass hybridization
bottle and sterilized with ethylene oxide gas. Once sterile, scaffolds were
pre-wet with 70% ethanol, washed 3 times with phosphate-buffered saline,
and immersed in a solution of 90% FBS and 10% antibiotic/antimycotic
(1–2 hours) while cells were prepared for seeding.
Valve Culture
MSCs were seeded onto the 80-cm2 scaffold at a density of 0.5 to 1.73
107 cells/cm2 by adding a dense cell suspension to the bottle housing the
scaffold. Valves were seeded in 60 mL of medium containing DMEM
high glucose, 20% FBS, 10% autologous sheep serum, 23 antibiotic/anti-
mycotic, 10-mmol/L HEPES buffer, 82-mg/mL ascorbic acid-2-phosphate,
and 2-ng/mL basic fibroblast growth factor. During seeding, the scaffold
was rotated at 1 rpm, and medium was changed every 12 hours. After 72
hours, the valve was removed from the glass bottle and placed in an 850-
cm2 roller bottle containing 500 mL of medium as above without sheep
serum. The medium was changed every 3 days for 1 month (Figure 2).
Preoperative Blood Preparation for
Cardiopulmonary Bypass
Blood donation bags were prepared with acid–citrate–dextrose buffer for
blood banking. An adult sheep was exsanguinated for blood donation; blood
was stored at 4C overnight and used for blood prime for cardiopulmonary
bypass.
Operation
Twenty-two autologous valves were prepared according to these
methods, 19 of which were implanted in vivo. The remaining 3 valves
served as in vitro controls and were analyzed in parallel to characterize tis-
sues at the time of implantation. At operation, a thoracotomy was performed
in the fourth intercostal space, and under cardiopulmonary bypass with
a beating heart, the native pulmonary valve cusps and a 1- to 2-cmmain pul-
monary artery segment were excised. The engineered valved conduit was
removed from the tension device and interposed between the cut pulmonary
artery segments (Figure 2). Epicardial echocardiography was performed to
evaluate valve function at implantation (Figure 3). Maximum transvalvular
pressure gradient was obtained by continuous-wave spectral Doppler
methods. In addition, a semiquantitative evaluation of proximal pulmonary
regurgitation was performed, on the basis of vena contracta color jet width
and the presence of retrograde diastolic flow in the main pulmonary artery:
trivial ¼ long-axis color jet width  1 mm; mild ¼ color jet width between
1 and 2 mm; moderate ¼ color jet width>2 mm but<50% of the conduit
width; severe¼ color jet width>50% of conduit width and presence of ret-
rograde diastolic flow in the main pulmonary artery. After chest closure, the
animal was transferred from the operating table to a recovery sling, allowed
to recover until in hemodynamically stable condition, allowed to wake from
anesthesia, and extubated. All tubes and drains were removed before return
to the cage on the evening of the operation.
MRI
At each experimental midpoint, animals underwent cardiac MRI (1.5 T
Achieva; Philips, Best, The Netherlands) while under general anesthesia.ery c March 2010
FIGURE 1. Schematic representation of the study design. MRI, Magnetic resonance imaging.
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SA 5-channel cardiac radiofrequency surface coil was used. After localizing
images were obtained, breath-hold electrocardiogram-gated steady-state
free precession sequences were obtained in long- and short-axis ventricular
planes and in the long- and short-axis planes to the valved conduit. In-plane
and through-plane velocities in the valved conduit were measured with an
electrocardiogram-gated velocity-encoded cine MRI pulse sequence. Ven-
tricular volumes and conduit flow and velocity data were analyzed offline
with commercially available software (Medis QMass and QFlow, Leiden,
The Netherlands). The smallest and largest graft diameters were measured
to evaluate graft size at each time point.
Valve Explant Procedure
At each experimental end point, under general anesthesia, epicardial
echocardiography was performed for evaluation of valve function, using
the same methods as those performed at valve implantation. Pressures
were directly measured from positions proximal and distal to the graft to de-
tect pressure gradients. The animal was exsanguinated via an aortic catheter,
and the animal’s lungs and heart were removed en bloc after cardiac arrest.
Smallest conduit diameter and 3 measurements of cusp size were directly
measured at the time of explant, including cusp distance from base to free
edge (length), free edge distance from commissure to commissure (width),
and distance from sinus to cusp free edge (depth). Valves were explanted
within 24 hours of implantation (n ¼ 7) and after 1, 6, 12, and 20 weeks
(n ¼ 3 each).
Histologic Analysis
Explanted specimens were photographed, dissected, embedded in
Tissue-Tek O.C.T. (Sakura Finetek USA, Inc, Torrance, Calif), frozen in
2-methylbutane, and stored until histologic staining. Frozen sections were
cut, and slides were stained for overall morphology by hematoxylin and
eosin.
Statistical Analysis
Data were analyzed by the STATA statistical package (STATA IC 10.1,
Stata Corporation, College Station, Tex). Analysis of variance (ANOVA)The Journal of Thoracic and Cawas performed to evaluate statistical significance between groups.
Wilcoxon–Mann–Whitney tests were performed to compare means of 2
groups. Mean values are reported as  standard deviation. Graphic repre-
sentations were constructed from data using STATA.RESULTS
Valve Fabrication and Implantation
MSCs were expanded and grown successfully for each
animal over 30  2 days to reach a total of approximately
1 billion cells (Figure 2, A). During the in vitro culture
period, cusp length and width decreased from the time of
scaffold assembly to the time of implantation (3.0  0.10
cm vs 2.5  0.16 cm for cusp length, Wilcoxon–Mann–
Whitney P< .001; 2.8  0.05 cm vs 1.62  0.23 cm for
cusp width, Wilcoxon–Mann–Whitney P< .001). Valved
conduit diameter remained stable during the culture period
(2.3  0.14 cm before cell seeding vs 2.3  0.07 cm at
the time of implantation; P ¼ 1.00). Valves were easily re-
moved from the tension device at the time of implantation
(Figure 2, B, C, and D). For successful implantation into
the pulmonary circulation, all valved conduits contained suf-
ficient extracellular matrix to withstand pulmonary pressure
without transmural permeability (Figure 2, E and F). Con-
duits retained surgical suture without tearing and exhibited
the gross physical appearance of tissue (Figure 2, E and F).
Animals in the early time point groups (24 hours and 1
week) were not humanely killed before explant, but died
spontaneously, without evidence of myocardial or valvular
dysfunction. Causes of unplanned death included pancytope-
nia (n¼ 2), aortic tear (n¼ 2), carotid artery monitoring linerdiovascular Surgery c Volume 139, Number 3 725
FIGURE 2. A, Phase contrast micrograph (310) of ovine mesenchymal stem cells. B, Assembled valve scaffold before seeding. C, Valved conduit after
1 month of in vitro culture, before implantation. D, Valved conduit mounted and sutured on tension device. E, Valve conduit after removal from tension device
and before in vivo implantation. F, Implanted valved conduit.
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Scomplication (n ¼ 1), central venous air (n ¼ 1), bleeding
(n¼ 1), and agitation and hypervagal bradycardia during an-
esthetic emergence (n¼ 2). Pancytopenia was thought to be
related to prebypass corticosteroid administration, although
not all animals became symptomatic of anemia. The ovine
aorta is particularly friable and difficult to cannulate, and
subsequent to two aortic tears, the carotid artery was selected
for arterial cannulation. Anesthetic emergence difficultiesFIGURE 3. Still echocardiographic image in diastole (A) and systole (B) after i
through leaflet cusps at 3 postoperative weeks, showing coapting leaflets in diasto
at 3 postoperative weeks showing no regurgitation (x-axis, time; y-axis, velocit
726 The Journal of Thoracic and Cardiovascular Surgwere treated with rectal chloral hydrate (20 mg/kg), which
allowed smooth emergence from anesthesia without agita-
tion or respiratory depression. The remaining animals recov-
ered well without signs of clinical illness. No infectious
complications were identified in our study animals.
At implantation, valves demonstrated excellent initial func-
tion (n ¼ 16 undergoing echocardiography), with a mean
transvalvular Doppler pressure gradient of 17  4 mm Hg.mplantation. Magnetic resonance imaging long view (C) and short view (D)
le (arrows). Flow image (E) and graphic representation (F) of flow velocities
y [m/s]).
ery c March 2010
FIGURE 4. A, Measurements of smallest and largest conduit diameters by magnetic resonance imaging. B, Comparison of conduit diameter at time of ex-
plant with diameter measured by magnetic resonance imaging. C, Comparison of cusp length (dark circles) and width (open circles) over the study period.
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STrivial regurgitationwas observed in 11 valves; the remaining
5 demonstrated mild regurgitation at the time of implantation
(Figure 3).
Valve Monitoring
Epicardial echocardiograms performed before death on
animals surviving 1 week or less showed valve function,
by Doppler pressure gradient and degree of regurgitation,
which was equivalent to valve function at the time of implan-
tation. MRI was successfully performed at the study mid-
point in 9 animals. By MRI, valvular regurgitation was first
detected at 3 weeks. Mean regurgitant fractions and peak
velocities measured by MRI (n ¼ 3 at each time point)
were as follows: 15.9%  9.0% and 1.6  0.08 m/s at 3
weeks; 32.0%  8.0% and 1.5  0.4 m/s at 6 weeks; and
21.7% 8.0% and 1.1 0.5m/s at 10weeks. ByMRI, there
were no statistical differences between time points (n ¼ 3 at
each time point) with regard to pulmonary regurgitant frac-
tion or transvalvular gradient (ANOVA P¼ .13 for regurgi-
tation and P¼ .44 for gradient). By comparison, aortic valve
regurgitant fractions were 3% or less at all time points. Qual-
itatively, the cusps moved well and coapted at 3 weeks, but
had somewhat restricted motion at 6 weeks, and were fixed
and attenuated at 10 weeks. Epicardial echocardiography
before planned death in the 6-week animals demonstrated
mild to moderate pulmonary regurgitation; at 12 and 20
weeks, animals showed moderate to severe regurgitation.
Valved Conduit Analysis
Over the in vivo time course of the experiment, the largest
and smallest conduit diameters did not change (ANOVA
P ¼ .54 for smallest and P ¼ .30 for largest diameter;
Figure 4, A). When graft diameter measurements were
made at similar time points (see Figure 1), there was no
difference in the measurements made from MRI images or
directly from explanted tissue (ANOVA P¼ .52; Figure 4, B).
At the time of explant of valved conduits in animal
groups at 12 weeks or more, dimensional changes of valved
conduit cusps were statistically significant, both for length
and width measurements (ANOVA at 12 weeks’ mean cusp
length 1.20  0.90 cm vs 2.25  0.27 cm at implantation,The Journal of Thoracic and CaP ¼ .016; 12 weeks’ mean cusp width 1.00  0.30 cm vs
1.95  0.05 cm at implantation, P ¼ .001; 20 weeks’ mean
cusp length 0.67  0.66 cm vs 2.25  0.27 cm at implan-
tation, P ¼ .001; 20 weeks’ cusp width 0.70  0.75 cm vs
1.95  0.05 cm at implantation, P< 0.001). Cusp length
decreased by 78.5%, and cusp width decreased by
64.1% from the time of implant to explant at 20 weeks
(Figure 4, C).
Implanted and explanted conduits exhibited the gross ap-
pearance of tissue (Figure 5). Conduits exhibited a curvature
reminiscent of the native pulmonary artery. Three tissue
layers, including a center areawith residual polymer,were vis-
ible at all timepoints.At 12weeks in vivo, 3 cuspswere visible
(Figure 5), althoughcusp tissue appeared stiff and increasingly
attenuated after 12 weeks (Figure 5, O). The attenuation of
cusp tissue over time was evident by the gross appearance
of specimens and by hematoxylin–eosin histologic features
(Figure 5). Over time, cell and extracellular matrix density
increased (Figure 5, B, E, H, K, and N).
DISCUSSION
In this series of implanted tissue-engineered heart valves,
we demonstrate that we could reproducibly fabricate and
implant tissue-engineered valved conduits that showed
excellent initial valve function and acceptable function at
short-term follow-up. MRI provided a noninvasive tool for
quantitatively and objectively evaluating valve function.
Over time, cusp dimensions decreased and were associated
with the development of pulmonary regurgitation. Valved
conduit diameter remained stable over 20 weeks in vivo,
without evidence of aneurysm formation or stenosis.
Adult progenitor stem cells have been widely investigated
in tissue engineering and regenerative medicine as multipo-
tent cell populations having the capacity for self-renewal and
differentiation toward multiple differentiated cell line-
ages.4,5,7-10 During fetal life, heart valves develop from
delamination of a specialized subpopulation of endothelial
progenitor cells that migrate and undergo endothelial–
to–mesenchymal transdifferentiation and eventually become
valve interstitial cells. To date, the steps by which these
developmental processes are governed are incompletelyrdiovascular Surgery c Volume 139, Number 3 727
FIGURE 5. Preimplant and explant tissue evaluation showing representative gross and histologic images at time points (A–C) before implant and after 1
(D–F), 6 (G–I), 12 (J–L), and 20 (M–O) weeks in vivo. Histologic images are stained with hematoxylin and eosin, photographed at 320, and oriented
with the cusp at the top and the conduit wall at the bottom of the image (C, cusp; S, sinus; W, conduit wall).
Evolving Technology/Basic Science Gottlieb et al
E
T
/B
Sunderstood.11,12 Owing to the complexity and currently in-
complete understanding of heart valve development, tissue
engineers have hypothesized that without directly engineer-
ing these steps, implanting precursor cells in the appropriate728 The Journal of Thoracic and Cardiovascular Surgbiochemical and mechanical environment may yield similar
tissues to those generated in embryologic development. In
addition, MSC and other adult progenitor stem cell popula-
tions are thought to be immunoprivileged and, as a result, areery c March 2010
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Sdesirable candidates for autologous and potentially alloge-
neic implants.13 MSCs were used in these experiments
because they are progenitor cells capable of differentiation
into multiple mesenchymal lineages, of which valve intersti-
tial cells represent our target mesenchymal cell population.
We demonstrate a novel device for in vitro culture onto
which a valved conduit scaffold can be reproducibly
mounted, sterilized, seeded with cells, maintained in 3-
dimensional culture, and removed for in vivo implantation.
In addition, the tension device prevented collapse of the con-
duit walls during culture and allowed culture of cusps in
a closed position.
Valves were harvested at early time points from animals
whose deaths were anticipated but not planned. Sheep dying
within the first day experienced complications unrelated to
the valve, such as aortic cannulation technical errors and dif-
ficulties with emergence from anesthesia. Subsequently,
technical and anesthetic difficulties were addressed, and at
the end of this series, survival was nearly 100%. With suffi-
cient experience with ruminant perioperative care, the sheep
model was found to be acceptable for long-term preclinical
studies of this tissue-engineered cardiovascular device.
Valved conduit implantation into the circulation requires
impermeability to transmural flow across the conduit wall,
as well as the ability to hold suture. Valves were cultured
as previously described in a proof-of-concept article from
our laboratory; valves fabricated in the prior investigation
demonstrated these required features.1 MSCs served as an
autologous source of cell-derived extracellular matrix, pro-
viding a barrier to bleeding across the highly porous nonwo-
ven scaffold material. Although sufficient extracellular
matrix was formed for hemostasis at the time of implanta-
tion, we have yet to understand whether the types of matrix
produced by these cells, and the remodeling valved conduits
undergo, simulate healthy, normal fetal or postnatal valve
matrix turnover. Previous investigations have observed
gross similarities in matrix composition between explanted
engineered valves and normal valve tissues1-3; however, de-
tailed information is not yet available regarding collagen and
glycosaminoglycan subtypes. Extracellular matrix mole-
cules and their breakdown products are known to function
as regulatory molecules in normal valves and vasculature
and are likely to have an influence on the eventual
engineered tissue composition.12,14 A comprehensive and
detailed investigation of normal and engineered valve extra-
cellular matrix may yield insight into favorable mechanisms
of in vivo engineered valve remodeling.
Heart valves represent a unique application in tissue engi-
neering in that they must demonstrate acceptable hemody-
namic function in both the short and long term. To be
clinically translatable, reliable methods for monitoring in
vivo valve function over time are required. Sheep (Ovis ar-
ies) are the most commonly used large animal model in car-
diac surgery inasmuch as they have similar hemodynamicsThe Journal of Thoracic and Cato humans and provide rigorous evaluation of long-term
valve degradation and calcification.1,3,15 Although transtho-
racic echocardiography has been performed in experimental
sheep models by other groups,16 the anatomy of the ovine
thorax provides unreliable echocardiographic windows,
which effectively precludes serial echocardiographic moni-
toring. This limitation of transthoracic echocardiography
led to the combined use of MRI and epicardial (open chest)
echocardiography.
Here, we demonstrate that cardiac MRI provides a valu-
able tool for monitoring tissue-engineered heart valve di-
mensions and function. In patients with tetralogy of Fallot,
MRI is currently used for evaluation of valve function
over time.17 We modified our clinical cardiac MRI protocols
to capture analogous information from experimental sheep
and conclude that these methods provide reliable, quantita-
tive, and noninvasive monitoring of implanted engineered
heart valves. Future clinical trials of engineered heart valves
should include serial assessment of valve dimensions and
function by MRI.
Conduit diameter remained stable over the time course of
the study. In contrast to acellular pulmonary conduits previ-
ously implanted into the circulation,18 these conduits
showed no evidence of aneurysm formation. In addition,
we saw no evidence of progressive conduit diameter reduc-
tion or the development of pressure gradients across the con-
duit over time. However, we did not observe conduit growth
over time, and this observation could represent a true lack of
growth or a consequence of a relatively short duration of fol-
low-up. At the time of implantation, the engineered conduit
diameter was oversized compared with the native vessel di-
ameter. Twenty weeks after implantation, our longest time
point, the engineered vessel diameter more closely matched
that of the native vessel. Thus, we were unable to determine
whether growth occurred in our engineered conduit.
Histologic characteristics of the valve cusp were similar to
previous in vivo results from our laboratory, demonstrating
a layered structure in explanted specimens.1We documented
increasing valvular regurgitation, corresponding to decreas-
ing cusp length over time. In a recent report, Flanagan and
colleagues19 report similar leaflet shortening and progres-
sive valve regurgitation of fibrin-based tissue-engineered
heart valves in a sheep model. As more is understood about
the cellular and molecular mechanisms involved in tissue-
engineered heart valve remodeling in vivo, the cause of these
potentially related observations will be elucidated.
In summary, we build on previous work with a set of re-
producible animal experiments, describing longitudinal
functional and structural changes in implanted tissue-engi-
neered valved conduits. In addition, we describe effective
implant monitoring by cardiac MRI. Reproducible, longitu-
dinal valve function data are required to make progress to-
ward the goal of a clinically implantable tissue-engineered
heart valve. Future planned analyses of explanted specimens,rdiovascular Surgery c Volume 139, Number 3 729
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profiles of explanted valves, will allow additional insight
into cellular and molecular mechanisms of the observed in
vivo remodeling of engineered heart valves. Additionally,
we plan rigorous evaluation of valves constructed identi-
cally, followed by bioreactor conditioning. Although im-
portant questions remain regarding the types of scaffold
materials and seeded cell types optimally used for heart valve
tissue engineering, the knowledge gained from the current
experiments will guide the next generation of valve design
criteria and future progress toward engineered valves for
pediatric application.20
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Dr Sunjay Kaushal (Chicago, Ill). I really enjoyed that talk. I
know these are very difficult experiments to perform. Could you
provide more details on the histology? For instance, was there
actual elastin formation at 20 weeks or how was the collagen
organized?
Dr Gottlieb. At this point we have hypotheses but no evidence,
and we are involved in detailed investigation of these specific
topics, including the presence or absence of elastin at all time points
and a description of the evolution of collagen in explanted tissues,
including collagen maturity and fiber orientation. Unfortunately, I
do not have those data available today.
Dr Kaushal. Was there growth in these valves over time? I
know it is a short period of time, but any hints that the valves
were growing?
DrGottlieb.We still are limited by sample size. Although this is
a large number of sheep for a preclinical study, we are still limited
by the statistical power of small samples. Therefore, we saw no dif-
ference between the time of implant and the time of explant over 20
weeks. However, we started with conduits that were oversized for
the native pulmonary artery, and by the time the 20-week implants
occurred, the native artery diameter and the conduit diameter were
matched. We did not observe a time point at which there would be
wall stress on the tissue-engineered conduit, which might result in
growth.
Dr Michael E. Jessen (Dallas, Tex). How much growth was
there in the animal? What kind of weight gain did it have over
the 20 weeks?
DrGottlieb.We implanted at 20 kg and explanted at 40 to 45 kg.
Dr. Jessen. So they doubled in size over that time interval?
Dr Gottlieb. That’s right.
Dr Jessen. Did you make any measurements of what happened
to the actual scaffolding material, the polyglycolic acid or the poly-
L-lactic acid?
Dr Gottlieb. That is an important point, particularly in light of
the area of the leaflet decreasing over time. We wonder whether
this represents loss of polymer, extracellular matrix, and/or cells,
or whether it represents a contraction or shrinkage of the tissue
and a stable number of fibers of the bioresorbable scaffolds that
are compressed into a smaller area. These are questions that will un-
dergo investigation in the short term.
Dr David Kalfa (Marseille, France). I really congratulate you
for this work, and I have 2 questions for you. First, concerningery c March 2010
Gottlieb et al Evolving Technology/Basic Sciencethe extracellular matrix Dr Kaushal just spoke about, did you eval-
uate the presence of elastic fibers in the extracellular matrix, at least
on a qualitative way, while waiting for detailed investigation to be
performed? Second, were you interested in cellular tracking?
Dr Gottlieb. Both are excellent questions. The elastin question I
have already spoken to.We do not have the complete data set yet on
elastin in all explanted tissues at all time points, so I am reluctant
to give information. But our preliminary data did not show much
elastin.
In terms of your second question about tracking cells, in our lab-
oratory previously there were experiments with small-scale scaf-
folds that were engineered into patches in which cells were
tracked. We have undertaken some other experiments on a mouse
scale where we can track cells using GFP labels. However, in our
sheep model, we require that the valved conduits produce sufficient
extracellular matrix to be hemostatic when implanted into the circu-
lation. It is established that introduction of labeling vectors can
cause changes in expression of a lot of different genes, not just in
the addition of a label. After transfecting our bone marrow–derived
MSCs with a GFP label, they made insufficient matrix to be hemo-
static in the circulation. Because of this limitation, labeled valved
conduits were unable to withstand pulmonary pressure. As a result,
we have not undertaken those projects because we have not found
a way yet to durably and accurately label cells in a large animal
analogous model.
Dr John S. Ikonomidis (Charleston, SC). These results are
clearly very encouraging because they illustrate the application of
some difficult technology, but at the same time they are disappoint-
ing because of the observation of failure of these conduits after only
20 weeks. My first question is, have you followed these animals out
longer to track the progression of conduit failure?
Second, can you speculate whether cations will be required to
prolong conduit durability?
DrGottlieb.Those are tough questions. To the first one, our lon-
gest duration in our laboratory to date has been 20 weeks, which is 5The Journal of Thoracic and Camonths. We see sufficient pulmonary regurgitation at that point to
end experiments. We see right ventricular dilation, so evidence of
relatively long-term valve regurgitation. We have not monitored
them longer than that. We are hopeful that we will have valve leaf-
lets that function better in the future, and we will then undertake
those longer-term experiments.
In terms of the disappointment associated with failure of the
valves, I think we can only make progress through an iterative pro-
cess in which we look at the modes of failure in an engineering ap-
proach. Our first analysis now is to try to understand what went
wrong. Our second move would be to identify the biology resulting
in valve failure, then to manipulate it in vitro, and then to try it again
in vivo.
Dr Jolanda Kluin (Utrecht, The Netherlands). Could you
briefly compare your results with the results of the 2000 paper by
Simon Hoerstrup of your institution?
Dr Gottlieb. Dr Hoerstrup’s work involved a polymer of poly-
glycolic acid that was dip coated in poly-4-hydroxybutyrate and
seeded with vascular cells. They were completely differentiated
cells from the carotid artery smooth muscle cells and endothelial
cells. To start, we had completely different models, both in terms
of scaffold polymer and in terms of cell. These variables are non-
trivial and can account for many differences that we have seen in
our preliminary analysis of these valves. His experiments involved
6 animals, 1 at each of 6 different time points. Our current experi-
ment is different because it involves a greater number of animals at
multiple time points. His was the proof-of-concept experiment; our
current work represents the test of statistical reproducibility. In the
current experiments, we have seen evidence of valve regurgitation,
which was potentially similar to the central valvular regurgitation,
mentioned but not quantitated in the Hoerstrup paper. This builds
on that work or the model that was established in that work with
different cell types and different scaffolds.
In terms of histology, we will have an opportunity to do a very
in-depth analysis and to report those results separately.rdiovascular Surgery c Volume 139, Number 3 731
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